Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.78 USD | -0.48% | -1.71% | +8.54% |
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The group shows a rather high level of debt in proportion to its EBITDA.
- With an expected P/E ratio at 36.43 and 26.06 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company appears highly valued given the size of its balance sheet.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+8.54% | 16.83B | B | ||
-4.77% | 182B | C+ | ||
+4.10% | 114B | C | ||
-3.85% | 67.76B | A | ||
+5.19% | 51.91B | B- | ||
+5.54% | 43.23B | B- | ||
+6.07% | 41.07B | B+ | ||
+23.81% | 32.07B | B | ||
+15.86% | 25B | A- | ||
-5.06% | 24.35B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AVTR Stock
- Ratings Avantor, Inc.